NCT00472953终止3 期
Inhaled Pre-prandial Human Insulin Versus Subcutaneous Injected Insulin Aspart in Subjects With Diabetes and Chronic Obstructive Pulmonary Disease: A 52-week Open Label, Multicentre, Randomized, Parallel Trial to Investigate Long-term Safety
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- To evaluate pulmonary safety comparing inhaled insulin to subcutaneous injections
研究概览
简要总结
This trial is conducted in Europe, Asia and South America. A one-year clinical trial to compare the safety of inhaled human insulin to subcutaneous insulin aspart in subjects with type 1 or type 2 diabetes and chronic obstructive pulmonary disease (COPD).
详细描述
The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronic Obstructive Pulmonary Disease
- •Type 1 or type 2 diabetes
- •HbA1c lower or equal to 11.0 %
- •Body Mass Index (BMI) lower or equal to 40.0 kg/m2
排除标准
- •Recurrent severe hypoglycaemia
- •Current smoking or smoking within the last 6 months
- •Other pulmonary disease including asthma
- •Proliferative retinopathy or maculopathy requiring acute treatment
研究组 & 干预措施
A
Experimental
干预措施: inhaled human insulin (Drug)
B
Active Comparator
干预措施: insulin aspart (Drug)
结局指标
主要结局
To evaluate pulmonary safety comparing inhaled insulin to subcutaneous injections
时间窗: After one year
次要结局
- Preprandial Insulin Doses(After one year)
- Patient Reported Outcomes(After one year)
- Diabetes control measured by change in HbA1c from baseline(After one year)
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
Safety and Efficacy of Inhaled Insulin in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00331604Novo Nordisk A/S618
终止
3 期
Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00469586Novo Nordisk A/S174
已完成
4 期
Human Insulin NPH and Insulin Aspart in Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT00597233Novo Nordisk A/S91
终止
3 期
Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00343980Novo Nordisk A/S363
终止
3 期
Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and AsthmaDiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1AsthmaNCT00523042Novo Nordisk A/S10